NCT06983743 - A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

December 1, 2028

Conditions

Metastatic Solid Tumors

Interventions

DRUG

ERAS-0015

ERAS-0015 Administered orally

DRUG

ERAS-0015 in combination

ERAS-0015 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.

Trial Locations (5)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

NEXT Virginia, Fairfax

34232

RECRUITING

Florida Cancer Specalists, Sarasota

75701

RECRUITING

University of Texas at Tyler, Tyler

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

Erasca, Inc.

INDUSTRY